The Licox system features comprise parallel five-day data storage and trending, touch-screen interface, compact and lightweight ergonomic design, and a direct plug-and-play interface with the company’s Camino ICP monitor.

These features make the device easier to monitor the neuro-compromised patient.

The new brain tissue oxygen monitoring system provides clinicians with early warning of hypoxic events and allows more timely intervention to restore oxygen delivery to the vital tissues of the brain.

Integra LifeSciences chief scientific officer Simon Archibald noted clinical practice and research demonstrate that advanced multi-parameter monitoring plays a critical role in the management of neurotrauma patients and in preventing or reducing secondary injuries caused by hypoxic events.

"The redesigned Licox system is a robust, practical and easy-to-use clinical tool for recording cerebral tissue oxygenation. Paired with the new Camino monitor, the Licox system creates our next-generation neuromonitoring platform designed to provide clinicians with critical insight into the cerebral oxygenation, ICP and brain temperature status of their patients," Archibald added.

The US Food and Drug Administration has granted 510(k) clearance for the new Licox system.

Integra LifeSciences will feature the Licox system at the Congress of Neurological Surgeons annual meeting, 19 October to 23 October 2013, in San Francisco, California.